Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH

Summary

The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening. Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.

Eligibility

Inclusion Criteria:

* Adults aged 18 years or older
* Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC/ERS guidelines
* Followed at the study center with a diagnosis of PAH
* Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval
* Availability of analyzable clinical, imaging, and hemodynamic data
* Willingness to participate in the study and provision of written informed consent

Exclusion Criteria:

* Age younger than 18 years
* Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH)
* Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval
* Incomplete clinical or imaging data preventing analysis
* Unavailable follow-up data

Conditions4

Browse More Trials